Jul. 26, 2012
The Chinese-French joint venture between the companies Tasly and Transgene will initially develop four of Transgene’s products in China. The JV will subcontract most of its research and development activities to Tasly and to third parties so as to focus on project management as well as on medical and regulatory development. A first clinical trial is expected to start in 2015.
Tasly and Transgene will respectively invest 5.3 and 2.6 million Euros in a first capital increase for the JV. Transgene will also contribute intellectual property rights so as to balance the equity ownership of the JV at 50:50 with Tasly.
The JV also intends to develop additional products, including non-Transgene products in-licensed for their development and commercialization.